

Diagnosed with Myositis?

Researchers are studying the safety and effectiveness of an investigational drug in adults, aged 18 years or older, with Myositis [also known as Idiopathic Inflammatory Myopathy (IIM)]



Who Can Take Part?

- 18 years old +
- Confirmed diagnosis of any of the following:
 - Polymyositis
 - Antisynthetase syndrome (ASyS)
 - Polymyositis overlap with Sjögren's Syndrome
 - Dermatomyositis
 - Juvenile Dermatomyositis (diagnosed within last 5 years)
 - Necrotizing myopathy
- There are additional requirements you must meet to take part in this study. A study representative will discuss these with you.



What Will The Study Involve?

- The study will last up to 38 weeks
- Screening period:
 - 1 visit at the study site
- Treatment period:
 - up to 24 weeks with a visit to the site every 4 weeks
- Weekly subcutaneous injection delivered into the layer beneath the skin, either at the study site, or at home
- Participants will continue to take their current medicines for myositis



Are There Any Costs?

- No study-related costs to participant
- Travel, accommodations, food and drink expenses reimbursed by study sponsor

Living with Myositis

Myositis is a disease in which the immune system mistakenly attacks the body's own cells, as it would attack a virus, with antibodies. This action triggers an internal inflammatory process that can destroy healthy, normal cells. This leads to muscle weakness and may affect other organs of the body.

The investigational study drug is currently not approved for use in myositis by any regulatory agency, as its safety and effectiveness have not been established for the treatment of myositis.

How Do I Participate?

Talk to your doctor about eligibility and share the study listing:
<https://clinicaltrials.gov/ct2/show/NCT05523167>

For more information about the ALKIVIA study and to get help with connecting to a study center, visit:
alkiviastudymyositis.com

Sources: 1. Data on file, argenx 2023 2. <https://clinicaltrials.gov/ct2/show/NCT05523167>
ALKIVIA Study Patient Infograph_V1_R3_25 October 2023

For Your Doctor



MED-US-ESC-2300010